Senestech (SNES) Stock Price, News & Analysis

Company Overview

SenesTech, Inc. (NASDAQ: SNES) is a biotechnology company specializing in non-lethal pest management solutions. The company’s core focus is the development and commercialization of fertility-based control methods for commensal rodents, providing an alternative to traditional rodenticides. By targeting the reproductive cycle of rats, SenesTech aims to reduce rodent populations over time without the use of toxic chemicals, offering a more sustainable approach for pest management professionals.

The company’s flagship product, ContraPest®, is an EPA-registered liquid bait that disrupts rodent reproduction. Administered through tamper-resistant bait stations, ContraPest delivers a proprietary formulation designed to lower fertility in target populations of Norway rats and roof rats. SenesTech complements its product offering with consultation and support services, assisting customers in designing monitoring programs, interpreting data, and implementing integrated pest management strategies tailored to municipal, commercial, and industrial settings.

Founded in 2001 and headquartered in Prescott, Arizona, SenesTech secured EPA approval for ContraPest in 2016, marking a milestone as the first fertility control agent for rodents available on the market. Since then, the company has expanded its distribution network across North America, serving food processing facilities, hospitality venues, healthcare institutions, warehouses, and municipal vector control agencies. SenesTech continues to pursue research and development of next-generation fertility control technologies and to explore potential applications in emerging global pest and wildlife management markets.

Led by an executive team with backgrounds in biotechnology, environmental science, and pest management, SenesTech is governed by a board of directors comprising industry experts in commercial product development and regulatory affairs. The company’s management structure supports ongoing collaboration with regulatory agencies and commercial partners to advance innovative solutions that address public health and sustainability concerns associated with rodent infestations.

Key Stats

• Today's Range: $1.59 to $1.65
• 50-Day Range: $1.42 to $1.97
• 52-Week Range: $1.41 to $6.24
• Volume: 69,857 shs
• Average Volume: 37,657 shs
• Market Capitalization: $8.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Senestech Stock Analysis - MarketRank™

Senestech scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

Senestech has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Senestech has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Senestech are expected to grow in the coming year, from ($1.57) to ($1.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Senestech is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Senestech is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Senestech has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.08% of the float of Senestech has been sold short.

Short Interest Ratio / Days to Cover

Senestech has a short interest ratio ("days to cover") of 0.88, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Senestech has recently decreased by 39.36%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Senestech does not currently pay a dividend.

Dividend Growth

Senestech does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

MarketBeat Follows

Only 1 people have added Senestech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.7 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Senestech in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $109,927.00 in company stock, which represents 1.2563% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Senestech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $109,927.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

2.20% of the stock of Senestech is held by insiders.

Percentage Held by Institutions

5.19% of the stock of Senestech is held by institutions.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 6/20/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Chemicals
• Current Symbol: NASDAQ:SNES
• CIK: 1680378
• Web: www.senestech.com
• Phone: (928) 779-4143
• Fax: N/A
• Employees: 30
• Year Founded: 2003

Profitability

• EPS (Trailing Twelve Months): ($1.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.38 million
• Net Margins: -304.22%
• Pretax Margin: -304.22%
• Return on Equity: -67.60%
• Return on Assets: -49.21%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 8.91
• Quick Ratio: 7.79

Sales & Book Value

• Annual Sales: $2.23 million
• Price / Sales: 3.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.83 per share
• Price / Book: 0.90

Miscellaneous

• Outstanding Shares: 5,303,000
• Free Float: 5,186,000
• Market Cap: $8.75 million
• Optionable: Not Optionable
• Beta: 0.28